Karyopharm Therapeutics (KPTI) EBIAT (2016 - 2025)
Karyopharm Therapeutics' EBIAT history spans 14 years, with the latest figure at -$102.2 million for Q4 2025.
- For Q4 2025, EBIAT fell 232.03% year-over-year to -$102.2 million; the TTM value through Dec 2025 reached -$196.0 million, down 156.52%, while the annual FY2025 figure was -$196.0 million, 156.52% down from the prior year.
- EBIAT reached -$102.2 million in Q4 2025 per KPTI's latest filing, down from -$33.1 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $38.7 million in Q4 2021 to a low of -$102.2 million in Q4 2025.
- Average EBIAT over 5 years is -$35.2 million, with a median of -$36.8 million recorded in 2022.
- Peak YoY movement for EBIAT: skyrocketed 189.17% in 2021, then crashed 256.57% in 2025.
- A 5-year view of EBIAT shows it stood at $38.7 million in 2021, then crashed by 199.45% to -$38.5 million in 2022, then fell by 8.65% to -$41.8 million in 2023, then rose by 26.43% to -$30.8 million in 2024, then plummeted by 232.03% to -$102.2 million in 2025.
- Per Business Quant, the three most recent readings for KPTI's EBIAT are -$102.2 million (Q4 2025), -$33.1 million (Q3 2025), and -$37.3 million (Q2 2025).